Absorbent article having test paper for leucorrhea, and test paper for leucorrhea to be used in absorbent article

Abstract

The purpose of the present invention is to provide an absorbent article and a test paper for the absorbent article in which a period suitable for natural pregnancy can be grasped at an earlier timing than before. An absorbent article according to the present disclosure has a test strip using immunochromatography for detecting luteinizing hormone (LH) from leucorrhea, the test strip being configured to estimate that a wearer of the absorbent article is in a period from five days before an ovulation day to the day of the ovulation day.

Description

Technical Field

[0001] The present invention relates to an absorbent article having a test paper for leucorrhea. In addition, the present invention relates to a test paper for leucorrhea to be used in an absorbent article. Further, the present disclosure also includes Invention B. Invention B will be described later. Background Art

[0002] It is important for women who wish to become pregnant to know in advance the ovulation day. As a method for predicting the ovulation day, a test for luteinizing hormone (LH) in urine is widely used.

[0003] In addition, an absorbent article having a detection site based on immunochromatography is known (Patent Document 1). According to this absorbent article, it is possible to grasp the health state by detecting the components of human excreta by means of an antigen-antibody reaction.

[0004] Prior art documents

[0005] Patent documents

[0006] Patent Document 1: Japanese Unexamined Patent Application Publication No. 2021-132724 Summary of the Invention

[0007] Problems to be Solved by the Invention

[0008] In the conventional ovulation day prediction method, particularly the prediction method using LH in urine, there are cases where the predicted ovulation day approaches, but the timing of natural conception is inappropriate and the opportunity is missed. In addition, in the prediction of the ovulation day based on the menstrual cycle, the accuracy of determining the ovulation day is low, and sometimes the results of natural conception cannot be obtained sufficiently. In addition, regarding the present disclosure, "natural conception" means having sexual intercourse for the purpose of having a baby.

[0009] Moreover, the conventional ovulation day prediction method using urine as a detection target has problems in terms of simplicity, and there are also problems such that the detection operation and the acquisition of results require time and effort.

[0010] An object of the present invention is to provide an absorbent article and a test paper for the absorbent article that can grasp the period suitable for natural conception at an earlier timing than in the past. In particular, an object of the present invention is to provide an absorbent article and a test paper for the absorbent article that can grasp the period suitable for natural conception at an earlier timing and with relatively high accuracy than in the past.

[0011] In addition, an object of the present invention is to provide an absorbent article and a test paper for the absorbent article that can predict the ovulation day more simply than in the past.

[0012] Means for Solving the Problems

[0013] An absorbent article of one mode has a test strip using an immunochromatographic method for detecting luteinizing hormone from vaginal discharge, wherein,

[0014] The test strip is configured to infer that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day.

[0015] An absorbent article of another mode contains the following X1 to X20:

[0016] <Mode X1>

[0017] An absorbent article having a test strip using an immunochromatographic method for detecting luteinizing hormone from vaginal discharge, wherein,

[0018] The test strip detects luteinizing hormone of 0.05 mIU / mL to 10 mIU / mL (especially 0.05 mIU / mL to 2.5 mIU / mL) as positive.

[0019] <Mode X2>

[0020] The absorbent article according to Mode X1, wherein,

[0021] The test strip has a width of 3 mm or less.

[0022] <Mode X3>

[0023] The absorbent article according to Mode X1 or X2, wherein,

[0024] The test strip has:

[0025] A first member that comes into contact with vaginal discharge;

[0026] A second member that contains a labeled antibody that recognizes luteinizing hormone in vaginal discharge; and

[0027] A third member that has a display portion containing a capture antibody,

[0028] The capture antibody can capture the complex formed by the binding of the labeled antibody and luteinizing hormone,

[0029] The test strip is configured such that luteinizing hormone in the vaginal discharge moves from the first member through the second member to the display portion of the third member, and

[0030] is configured such that the complex is captured by the capture antibody, thereby causing the display portion of the third member to develop color.

[0031] <Mode X4>

[0032] The absorbent article according to Mode X3, wherein,

[0033] The first member, the second member, and the third member are stacked at least partially overlapping in this order.

[0034] The sum of the thicknesses of the first member, the second member, and the third member in the stacking direction is 1.5 mm or less.

[0035] <Mode X5>

[0036] The absorbent article according to Mode X3 or X4, wherein

[0037] The first member is made of fibers having a fiber diameter of 0.5 μm to 5 μm (or a fineness of 0.01 dtex to 0.1 dtex).

[0038] The second member is made of fibers having a fiber diameter of 10 μm to 40 μm (or a fineness of 2 dtex to 6 dtex).

[0039] <Mode X6>

[0040] The absorbent article according to any one of Modes X3 to X5, wherein

[0041] The fiber diameter R1 of the fibers constituting the first member and the fiber diameter R2 of the fibers constituting the second member satisfy the relationship of 5 ≤ (R2 / R1) ≤ 20.

[0042] <Mode X7>

[0043] The absorbent article according to any one of Modes X3 to X5, wherein

[0044] The fineness D1 of the fibers constituting the first member and the fineness D2 of the fibers constituting the second member satisfy the relationship of 50 ≤ (D2 / D1) ≤ 200.

[0045] <Mode X8>

[0046] The absorbent article according to any one of Modes X3 to X7, wherein

[0047] The absorbent article satisfies at least one of the following conditions:

[0048] (a) The second member has a basis weight of 100 gsm or more.

[0049] (b) The sum of the thicknesses of the first member, the second member, and the third member is 1.5 mm or less, and the thickness of the second member occupies 30% or more of the sum of the thicknesses.

[0050] (b) The second member has 0.05 g / m 3~0.80 g / m 3 Density of

[0051] <Mode X9>

[0052] The absorbent article according to any one of Modes X3 to X8, wherein

[0053] The labeled antibody has a colorant with a particle size of 250 nm to 500 nm (preferably 280 nm to 450 nm, more preferably 300 nm to 400 nm).

[0054] <Mode X10>

[0055] The absorbent article according to any one of Modes X1 to X9, wherein

[0056] The absorbent article has a topsheet,

[0057] When using the absorbent article, the leukorrhea reaches the test strip through the topsheet.

[0058] <Mode X11>

[0059] The absorbent article according to Mode X10, wherein

[0060] The detection is performed by bringing at least a part of the topsheet into direct contact with the vagina.

[0061] <Mode X12>

[0062] The absorbent article according to Mode X10 or X11, wherein

[0063] The basis weight per unit area of the topsheet is 20 gsm or less.

[0064] <Mode X13>

[0065] The absorbent article according to any one of Modes X10 to X12, wherein

[0066] The thickness of the topsheet is 1 mm or less.

[0067] <Mode X14>

[0068] The absorbent article according to any one of Modes X10 to X13, wherein

[0069] The single fiber diameter of the fibers constituting the topsheet is 8.0 dtex or less.

[0070] <Mode X15>

[0071] The absorbent article according to Mode X10, wherein

[0072] The basis weight per unit area of the topsheet is 5 gsm or more,

[0073] the thickness of the topsheet is 0.1 mm or more, and

[0074] the single fiber diameter of the fibers constituting the topsheet is 1.0 dtex or more.

[0075] <Mode X16>

[0076] An absorbent article according to any one of Modes X10 to X15, wherein

[0077] the topsheet has an embossed pattern at least partially,

[0078] the width of the test strip is larger than the size and / or interval of each pattern of the embossed pattern.

[0079] <Mode X17>

[0080] An absorbent article according to any one of Modes X10 to X16, wherein

[0081] the topsheet has an embossed pattern locally,

[0082] the test strip can contact the leucorrhea through a portion of the topsheet that does not have the embossed pattern.

[0083] <Mode X18>

[0084] An absorbent article according to any one of Modes X10 to X17, wherein

[0085] the topsheet does not contain TiO 2 .

[0086] <Mode X19>

[0087] An absorbent article according to any one of Modes X10 to X18, wherein

[0088] the test strip has a sample pad that contacts the leucorrhea, and the sample pad is disposed at a position opposite to the vaginal part of the wearer during wearing,

[0089] the fiber diameter of the fibers constituting the sample pad is the same as or smaller than the fiber diameter of the fibers constituting the topsheet.

[0090] <Mode X20>

[0091] A test strip for an absorbent article, which uses an immunochromatographic method for detecting luteinizing hormone in leucorrhea, wherein

[0092] The test strip detects luteinizing hormone at 0.05 mIU / mL to 10 mIU / mL (especially 0.05 mIU / mL to 2.5 mIU / mL) as positive.

[0093] Effects of the Invention

[0094] According to the present invention, there can be provided an absorbent article capable of grasping the period suitable for natural conception at an earlier timing than before and a test strip for the absorbent article. In particular, according to the present invention, there can be provided an absorbent article capable of grasping the period suitable for natural conception at an earlier timing than before and with relatively high precision and a test strip for the absorbent article.

[0095] In addition, according to the present invention, there can be provided an absorbent article capable of predicting the ovulation day more simply than before and a test strip for the absorbent article. BRIEF DESCRIPTION OF THE DRAWINGS

[0096] Figure 1 It is a photograph showing the result of the sensitivity test of the test strip of the present invention.

[0097] Figure 2 It is a photograph showing the result of the luminescence intensity test of the test strip of the present invention.

[0098] Figure 3 It shows the result of the LH detection test of the present invention.

[0099] Figure 4 It shows the result of the LH detection test of the present invention.

[0100] FIG. 5-1 is a schematic top view of the absorbent article of the embodiment as viewed from the skin side.

[0101] FIG. 5-2 is a conceptual diagram of the specific structure of the test strip of the present invention.

[0102] FIG. 5-3 is a cross-sectional schematic view of the absorbent article of one embodiment of the present invention.

[0103] FIG. 5-4 is a cross-sectional schematic view of the absorbent article of one embodiment of the present invention.

[0104] FIG. 6-1 is a diagram for explaining the experimental example.

[0105] FIG. 6-2 is a diagram for explaining the experimental example.

[0106] FIG. 6-3 is a diagram for explaining the experimental example.

[0107] FIG. 6-4 is a diagram for explaining the experimental example.

[0108] FIG. 6-5 is a diagram for explaining the experimental example.

[0109] FIG. 6-6 is a diagram for explaining the experimental example.

[0110] FIGS. 6-7 are diagrams illustrating experimental examples.

[0111] Figure 7 is a top view of the topsheet 3 side of the sanitary napkin 1 according to the first embodiment of Invention B.

[0112] Figure 8 is a top view of the backsheet 5 side of the sanitary napkin 1 according to the first embodiment of Invention B.

[0113] Figure 9 is along the line Figure 1 III-III cross-sectional view.

[0114] Figure 10 is a top view of the topsheet 3 side of the test strip 21 according to Invention B.

[0115] Figure 11 is along the line Figure 4 V-V cross-sectional view.

[0116] Figure 12 FIGS. are diagrams illustrating experimental examples. DETAILED DESCRIPTION

[0117] The detailed content of the present invention is described below. In addition, more detailed specific embodiments of the above-described modes X1 to X20 can also be appropriately referred to the following description.

[0118] <Mode 1>

[0119] An absorbent article having a test strip using an immunochromatographic method for detecting luteinizing hormone (LH) from vaginal discharge, wherein

[0120] the test strip is configured to infer that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day.

[0121] As described above, in the conventional ovulation day prediction method, natural conception cannot sometimes be appropriately performed.

[0122] Specifically, for example, the LH peak in urine locally peaks in two days including the ovulation day. By using the LH value in urine, two days including the ovulation day can be determined. However, by checking the LH in urine, even if the user knows the two days including the ovulation day, ovulation may be approaching and natural conception cannot be predicted, so natural conception cannot be performed even if the ovulation day is known.

[0123] In addition, to facilitate the planning of natural conception, ovulation days are predicted based on the menstrual cycle. However, in the prediction of ovulation days based on the menstrual cycle, the accuracy of determining ovulation days is low, and the results of natural conception cannot be fully achieved. Generally speaking, menstruation occurs around 14 days after the ovulation day, but sometimes it varies depending on changes in physical condition, etc., and it only gives a rough indication of the ovulation day.

[0124] In contrast, the absorbent article of the above-mentioned Mode 1 has a test strip using an immunochromatographic method for detecting luteinizing hormone (LH) from vaginal discharge, and this test strip is configured to infer that the wearer of the absorbent article is in the natural conception period from 5 days before the ovulation day to the ovulation day itself. More specifically, the absorbent article of the above-mentioned Scheme 1 detects luteinizing hormone (LH) in the vaginal discharge excreted during the natural conception period from 5 days before the ovulation day to the ovulation day itself, for example, by color development, etc., whereby it is possible to determine with relatively high accuracy that the wearer is in the natural conception period from 5 days before the ovulation day to the ovulation day itself.

[0125] The invention of this Mode 1 is based on such a new insight: by paying attention to LH in vaginal discharge, it is possible to predict the scheduled ovulation day earlier than before. That is, the inventors of this case have found that by using LH in vaginal discharge as the detection object, it is possible to determine with a relatively high probability that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day itself (the period suitable for natural conception).

[0126] According to this Mode 1, compared with the case where the LH peak in urine is used as an indicator, the ovulation day can be grasped from an earlier period, so the possibility of ensuring more opportunities for natural conception is increased, and natural conception can be planned in advance. In addition, compared with the conventional method of being able to grasp the situation on the ovulation day or the day before, it is possible to reduce the burden of having to schedule natural conception on the day or the day before or two days before, and / or to suppress the situation where natural conception cannot be carried out due to the inability to plan in advance. As a result, it is possible to improve the execution of natural conception while reducing the mental burden.

[0127] Moreover, the absorbent article of Mode 1 has a test strip using an immunochromatographic method for detecting luteinizing hormone from vaginal discharge, so compared with existing technologies such as using the menstrual cycle as an indicator, the natural conception period can be grasped with relatively high accuracy.

[0128] Furthermore, the absorbent article for absorbing vaginal discharge is a commonly used item. Therefore, for the absorbent article of Mode 1 of the present invention, the user can perform the examination by wearing this absorbent article in the same way as the commonly worn absorbent article.

[0129] Moreover, since the inspection result of leucorrhea is awaited in the wearing state, unlike the inspection member using urine, there is no need for only the time for awaiting the inspection result, and thus the mental and time burdens of the inspection can be alleviated.

[0130] The natural conception period to which the test strip of Method 1 can respond can be further defined. For example, it can also be the natural conception period from 5 days before the ovulation day to the day before the ovulation day, the natural conception period from 5 days before the ovulation day to 2 days before the ovulation day, the natural conception period from 5 days before the ovulation day to 3 days before the ovulation day, or further the natural conception period from 5 days before the ovulation day to 4 days before the ovulation day.

[0131] When detecting LH in leucorrhea, it is not always possible to detect only the above-mentioned specific natural conception period. However, when detecting LH in leucorrhea, the ovulation day can be predicted at an earlier stage than before, and thus it is possible to determine with a higher probability than before that the wearer is in the above natural conception period.

[0132] <Method 2 and Method 3>

[0133] An absorbent article having a test strip using immunochromatography for detecting luteinizing hormone from leucorrhea, wherein

[0134] The test strip detects luteinizing hormone of 0.05 mIU / mL to 10 mIU / mL as positive.

[0135] As described above, in the conventional ovulation day prediction methods, the method usually uses urine as the detection object. In contrast, the inventor of the present case focused on leucorrhea as the detection object used for predicting the ovulation day. There have been few discoveries regarding luteinizing hormone (LH) in leucorrhea so far, but according to the absorbent article of the present case having a test strip that detects luteinizing hormone of 0.5 mIU / mL to 10 mIU / mL as positive, luteinizing hormone in leucorrhea can be detected with high reliability.

[0136] In addition, according to the absorbent article of the present case, different from the conventional inspection method for luteinizing hormone (LH) in urine, in terms of not requiring conscious extraction, etc., the ovulation day can be predicted with high reliability while reducing the burden on the user.

[0137] Moreover, the absorbent article of the present case is different from the conventional inspection kit for luteinizing hormone (LH) in urine and is an article for daily use. Therefore, the ovulation day can be predicted very simply, and in addition, it also has the effect of causing less psychological resistance.

[0138] In addition, in the conventional immunoassay chromatography method, operations such as bringing urine into contact with a test strip are required for detection. In addition, it sometimes takes a relatively long time (for example, 10 minutes). However, according to the absorbent article of the present case, since simply wearing the absorbent article enables a detection reaction to occur along with the discharge of secretions, the prediction of the ovulation day becomes more convenient. For example, according to the absorbent article of the present case, instead of waiting for 10 minutes to confirm the test result, the test result can be confirmed, for example, when going to the bathroom at a time more than 10 minutes after wearing the absorbent article, so it is more convenient.

[0139] In addition, different from the conventional case of using urine, the absorbent article of the present case also has the advantage that detection can be performed without worrying about dirtying hands.

[0140] As described above, according to the invention of Mode 2 of the present application, an absorbent article capable of predicting the ovulation day more simply than in the past can be provided.

[0141] In addition, although the concentration of LH in urine sometimes varies significantly depending on factors such as water intake, in the case of leucorrhea, the concentration of LH may be relatively stable. Therefore, by using leucorrhea as the detection target, effects that cannot be obtained when using urine as the detection target may also be brought about.

[0142] The detailed structure of the absorbent article of the above-mentioned Mode 1, that is, the absorbent article having a test strip configured to be used for inferring that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day itself, is not particularly limited. For example, it can be realized by using the test strip of the following Mode 2.

[0143] Although there is no intention to limit based on theory, in the conventional urine test strip, since the amount of luteinizing hormone (LH) to be detected is relatively large, the detection sensitivity is accordingly set relatively low. In contrast, in the invention of Mode 2 of the present invention, in order to detect a relatively small amount of leucorrhea luteinizing hormone, the detection sensitivity is set relatively high compared to the conventional urine test strip. Therefore, according to the absorbent article of Mode 2 of the present invention, it is also possible to detect the rise of luteinizing hormone at an earlier stage that could not be detected in the past. As a result, it is considered possible to grasp an earlier stage before the ovulation day.

[0144] The test strip of the above-mentioned Mode 2 detects luteinizing hormone with a concentration of 0.05 mIU / mL to 5 mIU / mL, more preferably 0.05 mIU / mL to 2.5 mIU / mL (Mode 3 of the present invention), and particularly preferably 0.05 mIU / mL to 2.0 mIU / mL as positive.

[0145] The lower limit of the concentration of luteinizing hormone for which the test strip detects as positive is more preferably 0.1 mIU / mL, 0.4 mIU / mL, or further 0.5 mIU / mL.

[0146] The test strip of the above-described Method 2 can perform a positive detection by color development when, for example, the luteinizing hormone is within the above-described concentration range or an appropriate concentration range.

[0147] In addition, in the test strip of the above-described Method 2, when, for example, the luteinizing hormone is within the above-described concentration range or an appropriate concentration range, it can develop color to a degree lower than the maximum color development degree. The degree of color development can be confirmed visually, for example.

[0148] A test strip that can detect the above-described concentration range or appropriate concentration range as positive can be produced, for example, by adjusting the sensitivity of a substance (such as an antibody) that reacts with the luteinizing hormone (such as a coloring agent), and in particular, can be produced by adjusting the size of the coloring agent attached to the antibody that recognizes the luteinizing hormone.

[0149] In particular, the test strip detects as positive the following luteinizing hormone:

[0150] More preferably, luteinizing hormone of 0.05 mIU / mL to 1.0 mIU / mL,

[0151] Even more preferably, luteinizing hormone of 0.05 mIU / mL to 0.5 mIU / mL,

[0152] Even further preferably, luteinizing hormone of 0.05 mIU / mL to 0.2 mIU / mL.

[0153] The detection concentration of the test strip can be measured using a casein blocking buffer of LH as a standard solution.

[0154] For example, a casein blocking buffer of LH can be prepared by the following method:

[0155] (a) Dissolve a casein blocking agent (1.0% Casein, 100 mM Borate, pH 8.5) in purified water to prepare a blocking buffer.

[0156] (b) Dilute a solution of LH with a known concentration with the blocking buffer to prepare a standard solution of LH.

[0157] For example, a casein blocking agent can be prepared as follows:

[0158] (1.0% Casein, 100 mM Borate, pH 8.5)

[0159] (a) Add 800 g of distilled water to a 1000 ml beaker.

[0160] (b) Add 2.0 ml of 20% NaOH.

[0161] (c) Stir for 10 minutes.

[0162] (d) Slowly add 10.0 g of casein powder.

[0163] (e) Stir for 3 hours.

[0164] (f) 6.18 g of boric acid (= add 100 mM).

[0165] (g) Stir for 10 minutes.

[0166] (h) Add 2.5 ml of 20% NaOH.

[0167] (i) Dilute to 1000 ml with distilled water.

[0168] (j) Stir for 10 minutes.

[0169] (k) Measure the pH.

[0170] (l) Filter using a filter unit (pore size 0.45 μm).

[0171] (m) Perform heat treatment at 30 °C for 24 hours.

[0172] (n) Aliquot into 15 ml or 50 ml containers for storage.

[0173] (o) Store at -80 °C.

[0174] In addition, according to the existing literature, the natural LH peak concentration in urine is 20 mIU / ml to 100 mIU / ml (Bioeng. Transl. Med., 2017, 2(3): 238 - 246). Conventional luteinizing hormone test kits using urine test samples have a detection sensitivity range of 20 mIU / mL to 100 mIU / mL for luteinizing hormone in urine (Ministry of Health, Labour and Welfare of Japan, Pharmaceutical Affairs Bureau Notice No. 0222, February 22, 2016).

[0175] <Mode 4>

[0176] According to the absorbent article described in any one of Modes 1 to 3, wherein

[0177] the test strip has a width of 10 mm or less.

[0178] The width of the test strip is preferably 1 mm to 6 mm, more preferably 1 mm to 3 mm. From the viewpoints of visual recognition and processability by the user, the width of the test strip is preferably 1 mm or more, more preferably 2 mm or more.

[0179] In the absorbent article of Mode 4, since the width of the test strip is reduced to less than 10 mm, particularly less than 3 mm, the amount of liquid that needs to be retained for detection is relatively reduced. Therefore, according to the invention of Mode 4, even when detecting leucorrhea with a small amount, high viscosity, and a small amount of LH as the detection target, the detection of LH can be performed well.

[0180] In addition, when the width of the test strip is 10 mm or less, damage to the labia during the use of the absorbent article can be avoided.

[0181] Furthermore, according to Mode 4, since the width of the test strip is small, there is also an additional effect of reducing the discomfort when wearing the absorbent article.

[0182] <Mode 5>

[0183] The absorbent article according to any one of Modes 1 to 4, wherein

[0184] the test strip has:

[0185] a second member containing a labeled antibody that recognizes luteinizing hormone in leucorrhea; and

[0186] a third member having a display portion containing a capture antibody,

[0187] the capture antibody can capture the complex formed by the binding of the labeled antibody and luteinizing hormone,

[0188] the test strip is configured such that luteinizing hormone in the leucorrhea moves from the second member to the display portion of the third member, and

[0189] is configured such that the capture antibody captures the complex, thereby causing the display portion of the third member to develop color.

[0190] The absorbent article according to Mode 5 can simply and rapidly detect luteinizing hormone by means of a color reaction.

[0191] The method of introducing leucorrhea (or leucorrhea components) into the test strip is not particularly limited. For example, it can be introduced by bringing leucorrhea into local contact with the test strip.

[0192] In one mode of the absorbent article of the present disclosure, the test strip has a first member that contacts leucorrhea. In this case, the test strip can be configured such that luteinizing hormone in leucorrhea moves from the first member via the second member to the display portion of the third member.

[0193] In particular, the absorbent article of the present disclosure also includes the following mode:

[0194] The absorbent article according to any one of Modes 1 to 4, wherein,

[0195] The test strip has:

[0196] A first member that comes into contact with leucorrhea;

[0197] A second member that contains a labeled antibody that recognizes luteinizing hormone in leucorrhea; and

[0198] A third member that has a display portion containing a capture antibody,

[0199] The capture antibody can capture the complex formed by the binding of the labeled antibody and luteinizing hormone,

[0200] The test strip is configured such that luteinizing hormone in the leucorrhea moves from the first member through the second member to the display portion of the third member, and

[0201] It is configured that the capture antibody captures the complex, whereby the display portion of the third member develops color.

[0202] A specific example of use is used to illustrate the measurement principle of the test strip. In the exemplified mode, for example, the labeled antibody is a coloring agent-labeled anti-human luteinizing hormone mouse monoclonal antibody, and the capture antibody is an anti-human luteinizing hormone mouse monoclonal antibody. If human luteinizing hormone (hLH) is present in the sample in contact with the first member, then in the second member, the labeled antibody reacts with hLH to form a complex based on the antigen-antibody reaction. This complex moves to the display portion of the third member and is captured by the capture antibody fixedly bound thereto. As a result, the display portion develops color based on the coloring agent (pigment).

[0203] In addition, a second display portion (control portion) can be provided on the downstream side in the moving direction of the antigen in the display portion. A second capture antibody (for example, rabbit anti-mouse immunoglobulin polyclonal antibody) different from the above-mentioned capture antibody is fixedly bound to this control portion. This second capture antibody can recognize the labeled antibody. Since the labeled antibody that has not formed a complex with the antigen is not captured by the display portion but passes through the display portion and is captured by the control portion, as a result, the control portion develops color based on the coloring agent.

[0204] In this mode, in the case of a positive result, the display portion and the control portion develop color, and in the case of a negative result, only the control portion develops color.

[0205] The structure of the test strip will be described in detail later.

[0206] <Mode 5b>

[0207] In one embodiment of the absorbent article of the present disclosure, the first member, the second member, and the third member of the test strip are laminated at least partially overlapping each other in this order.

[0208] The sum of the thicknesses of the first member, the second member, and the third member in the lamination direction is 1.5 mm or less.

[0209] As described above, leucorrhea has relatively high viscosity and low fluidity. In addition, the amount of leucorrhea is less than that of urine and the like. Therefore, especially in the detection using the immunochromatography method, it is sometimes not easy to detect LH in leucorrhea by the conventional method.

[0210] In addition, the inventors of the present case found that the amount of LH in leucorrhea is less than the amount of LH in urine. In the conventional test strips, it is not easy to detect LH in leucorrhea.

[0211] In contrast, in the absorbent article of the above-described embodiment 5b, since the thickness of the members constituting the test strip is small, the amount of liquid required to be held on the test strip for detection is relatively reduced. Therefore, according to the absorbent article of embodiment 5b, even when leucorrhea having a small amount, high viscosity, and a small amount of LH is used as a detection target, LH can be detected well.

[0212] The preferred range of the thickness (film thickness) of each member is not particularly limited, and is, for example, 160 μm to 230 μm, and more preferably 180 μm to 220 μm.

[0213] <Mode 5c>

[0214] In one embodiment of the absorbent article of the present disclosure, the first member is made of fibers having a fiber diameter of 0.5 μm to 5 μm (or a fineness of 0.01 dtex to 0.1 dtex).

[0215] The second member is made of fibers having a fiber diameter of 10 μm to 40 μm (or a fineness of 2 dtex to 6 dtex).

[0216] As described above, leucorrhea has relatively high viscosity and low fluidity. Therefore, especially in the detection using the immunochromatography method, it is sometimes not easy to detect LH in leucorrhea. In addition, the inventors of the present case found that the amount of LH in leucorrhea is less than the amount of LH in urine.

[0217] In contrast, in the test strip of the above-described embodiment 5c, since the fiber diameter (or fineness) of the members constituting the test strip is optimized, even a small amount of leucorrhea with high viscosity can be efficiently moved to the detection site (display part), and detection can be performed well.

[0218] The first component is preferably made of fibers having a fiber diameter of 1 μm to 4 μm, more preferably 1.5 μm to 3 μm.

[0219] The first component is preferably made of fibers having a fineness of 0.02 dtex to 0.08 dtex, more preferably 0.03 dtex to 0.06 dtex.

[0220] The second component is preferably made of fibers having a fiber diameter of 15 μm to 30 μm, more preferably 18 μm to 25 μm.

[0221] The second component is preferably made of fibers having a fineness of 2.5 dtex to 5 dtex, more preferably 3 dtex to 5 dtex.

[0222] <Mode 5d>

[0223] In one embodiment of the absorbent article of the present disclosure, the fiber diameter R1 of the fibers constituting the first component and the fiber diameter R2 of the fibers constituting the second component satisfy the relationship of 5 ≤ (R2 / R1) ≤ 20.

[0224] According to this mode, since the correspondence relationship between the fiber diameters of the first component and the second component constituting the test strip is optimized, as a result, even a small amount of leucorrhea with high viscosity can be efficiently moved to the detection part (display part), and the detection can be performed well.

[0225] In a more preferred mode, it satisfies

[0226] 6 ≤ (R2 / R1) ≤ 18,

[0227] 7 ≤ (R2 / R1) ≤ 16,

[0228] 8 ≤ (R2 / R1) ≤ 14,

[0229] 9 ≤ (R2 / R1) ≤ 12.

[0230] <Mode 5e>

[0231] In one embodiment of the absorbent article of the present disclosure, the fineness D1 of the fibers constituting the first component and the fineness D2 of the fibers constituting the second component satisfy the relationship of 50 ≤ (D2 / D1) ≤ 200.

[0232] According to this mode, since the correspondence relationship between the finenesses of the first component and the second component constituting the test strip is optimized, as a result, even a small amount of leucorrhea with high viscosity can be efficiently moved to the detection part (display part), and the detection can be performed well.

[0233] In a more preferred embodiment, it satisfies

[0234] 60 ≤ (D2 / D1) ≤ 190,

[0235] 70 ≤ (D2 / D1) ≤ 180,

[0236] 80 ≤ (D2 / D1) ≤ 170,

[0237] 90 ≤ (D2 / D1) ≤ 160.

[0238] <Mode 5f>

[0239] One embodiment of the absorbent article of the present disclosure satisfies at least one of the following conditions:

[0240] (a) The second member has a basis weight of 100 gsm or more,

[0241] (b) The sum of the thicknesses of the first member, the second member, and the third member is 1.5 mm or less, and the thickness of the second member occupies 30% or more of the sum of the thicknesses,

[0242] (c) The second member has a density of 0.05 g / m 3 ~0.80 g / m 3 of.

[0243] According to this mode, the basis weight, thickness, and / or density of the second member (for example, a conjugate pad) are optimized, whereby the diffusibility of the labeled antibody and the like are improved. Therefore, even for leucorrhea with a relatively high viscosity, detection can be performed well. In addition, within this range (especially the range of (c)), good liquid transferability and color development can be ensured.

[0244] <Mode 6>

[0245] For the absorbent article according to Mode 5, wherein

[0246] The labeled antibody has a coloring agent with a particle size of 250 nm to 500 nm (preferably 280 nm to 450 nm, more preferably 300 nm to 400 nm).

[0247] As described above, the inventors of the present case found that the amount of LH in leucorrhea is less than the amount of LH in urine. In this case, it is not easy to detect LH in leucorrhea with conventional test strips (especially those targeting LH in urine).

[0248] In contrast, in the test strip of Mode 6, since the labeled antibody that binds to LH has a coloring agent with a relatively large particle size, the visual recognition of the detection is improved. Therefore, even when detecting a small amount of LH in leucorrhea as the detection target, the detection of LH can be performed well.

[0249] <Mode 7>

[0250] The absorbent article according to Mode 5 or 6, wherein

[0251] The test strip has a moving part connecting the second member and the display part, and has a first direction as the moving direction of the leucorrhea component from the moving part to the display part, a second direction orthogonal to the first direction, and a thickness direction orthogonal to the first direction and the second direction.

[0252] The test strip has a central region located in the center in the second direction and side regions located at both ends in the second direction in the region where the test strip is divided into five equal parts in the second direction.

[0253] The moving part and the display part are at least disposed in the central region and the side regions.

[0254] The maximum thickness of the central region is thicker than the maximum thickness of the side regions, and / or the average thickness of the central region is thicker than the average thickness of the side regions.

[0255] In the test strip of the absorbent article of Mode 7, the average thickness of the central region is thicker than the average thickness of the side regions, and a relatively large volume of the space for the movement of excretory components can be ensured. As a result, in the central region, the leucorrhea component is likely to move along the first direction, and the display part in the central region is likely to show a color reaction. By showing the color reaction at the center in the second direction of the test strip, the wearer can easily visually recognize the color reaction, and the visual recognition of the inspection result can be improved. In addition, particularly, the above-mentioned first direction and second direction can also be defined in the plane of the test strip. In this case, the second direction is orthogonal to the first direction in the plane of the test strip. The above-mentioned divided regions into five equal parts, particularly the central region and the side regions, can extend along the first direction.

[0256] <Mode 8>

[0257] The absorbent article according to any one of Modes 5 to 7, wherein

[0258] The display part of the test strip can be visually recognized from the skin side of the absorbent article.

[0259] The test strip includes:

[0260] A transfer inhibition upper layer that inhibits the transfer of the wearer's excrement to the display portion of the test strip; and

[0261] A transfer inhibition lower layer that inhibits the transfer of the wearer's excrement to the display portion,

[0262] The transfer inhibition upper layer and the transfer inhibition lower layer abut against each other on the outside of the test strip in the width direction of the test strip.

[0263] In the absorbent article of Mode 8, since the test strip has a transfer inhibition upper layer and a transfer inhibition lower layer, and these layers abut against each other on the outside of the test strip in the width direction of the test strip, it is possible to inhibit the accidental mixing of excrement (leukorrhea) from the width direction and / or the thickness direction of the test strip. In particular, it is possible to inhibit the transfer of excrement (especially leukorrhea) directly to the display portion without passing through the sample pad and the conjugate pad of the test strip. As a result, the absorbent article can detect the antigen contained in leukorrhea in a state not easily affected by leukorrhea and the like.

[0264] More specifically, the transfer inhibition upper layer and the transfer inhibition lower layer abut against each other on the outside of the test strip in the width direction, for example, means that the both end portions in the width direction of the transfer inhibition upper layer and the transfer inhibition lower layer extend beyond the both end portions in the width direction of the test strip and abut against each other. That is, for example, when viewed from the skin side, the transfer inhibition upper layer and the transfer inhibition lower layer have a width wider than that of the test strip, and the both end portions in the width direction abut against each other.

[0265] The "transfer inhibition lower layer" can inhibit the transfer of the excrement absorbed by the absorbent body to the display portion, for example, when the test strip is disposed between the topsheet and the absorbent body.

[0266] In addition, in the absorbent article of Mode 8, since the test strip can be visually recognized from the skin side of the absorbent article, the position of the test strip of the absorbent article can be grasped when wearing, and the test strip can be disposed at an appropriate position. In addition, since the test strip can be visually recognized from the skin side, by visually recognizing the absorbent article from the skin side of the absorbent article, the inspection result can be grasped without peeling the absorbent article from the wearing article or taking off the absorbent article from the wearing article.

[0267] The transfer inhibition upper layer and the transfer inhibition lower layer can each be a sheet, for example, a sheet made of a hydrophobic material, especially a liquid-impermeable sheet. This liquid-impermeable sheet has lower air permeability compared to a sheet having an inter-fiber distance such as a non-woven fabric.

[0268] By sandwiching the test strip with two sheets as the transfer inhibition upper layer and the transfer inhibition lower layer, the inspection object can be retained, and in addition, the drying of the test strip can be prevented. That is, an appropriate humidity can be maintained, and after introducing leukorrhea and leukorrhea components, the leukorrhea components and the like can move smoothly, and the inspection can be appropriately performed.

[0269] The "transfer-inhibition upper layer" and the "transfer-inhibition lower layer" have a sealing portion that seals their outer edges. In particular, the sealing portion is formed at least along both end portions in the width direction of the test strip, so that the transfer of excrement (especially leukorrhea) to the test strip can be inhibited.

[0270] The "transfer-inhibition upper layer" and the "transfer-inhibition lower layer" are preferably configured to not only inhibit the transfer of the wearer's excrement to the display portion of the test strip, but also inhibit its transfer to the moving portion of the test strip (e.g., Figure 1 reference numeral 66A in the drawing). For example, when viewed from the skin side, the "transfer-inhibition upper layer" and the "transfer-inhibition lower layer" may be arranged to at least overlap with and cover the display portion and the moving portion of the test strip.

[0271] <Mode 9>

[0272] The absorbent article according to any one of Modes 1 to 8, wherein

[0273] the absorbent article has a topsheet,

[0274] when using the absorbent article, the leukorrhea reaches the test strip via the topsheet.

[0275] According to the invention of Mode 9, the discomfort during wearing caused by the test strip can be alleviated by the topsheet. In addition, even when urine is discharged, the urine spreads over the topsheet, so that the situation where the urine contacts the test strip and hinders the detection can be avoided or reduced.

[0276] <Mode 10>

[0277] The absorbent article according to Mode 9, wherein

[0278] the absorbent article has a front-back direction, a width direction orthogonal to the front-back direction, and a thickness direction orthogonal to the front-back direction and the width direction,

[0279] in the thickness direction, starting from the skin side of the wearer during use, there are further provided the topsheet and an absorbent body containing an absorbent material in sequence,

[0280] the test strip is disposed between the topsheet and the absorbent body.

[0281] According to Mode 10, since the test strip is disposed between the topsheet and the absorbent body (absorbent core), during the transfer of the excreted leukorrhea to the absorbent article, the leukorrhea can be efficiently transferred to the test strip (especially the first member of the test strip).

[0282] <Mode 11>

[0283] The absorbent article according to Mode 9 or 10, wherein

[0284] The test strip has:

[0285] A second member that contains a labeled antibody that recognizes luteinizing hormone in vaginal discharge; and

[0286] A third member that has a display portion containing a capture antibody,

[0287] The capture antibody is capable of capturing a complex formed by the binding of the labeled antibody and luteinizing hormone,

[0288] The test strip is configured such that luteinizing hormone in the vaginal discharge moves from the second member to the display portion of the third member, and

[0289] is configured such that the capture antibody captures the complex, whereby the display portion of the third member develops color,

[0290] A skin-side sheet having a coloring region is disposed at a position closer to the skin side than the test strip,

[0291] The labeled antibody in the second member of the test strip has a coloring agent,

[0292] When viewed from the skin side, the labeled antibody in the second member is covered by the coloring region of the skin-side sheet.

[0293] According to Mode 11, when viewed from the skin side, the colored labeled antibody in the second member (e.g., conjugate pad) of the test strip is covered by the coloring region of the skin-side sheet. According to such a mode, when the user visually recognizes the absorbent article before use from the skin side, it is difficult to visually recognize the colored labeled antibody, and misrecognition that the test member has reacted before using the absorbent article can be suppressed.

[0294] In addition, since the labeled antibody in the second member (especially the reaction portion) of the test strip is colored, compared with a structure in which the labeled antibody is not colored, not only the labeled antibody but also the complex is conspicuous relative to the surroundings. Therefore, during the inspection process, regions other than the colored portion of the display portion are also colored, indicating that the inspection is in progress. And after the inspection is completed, the complex and the display portion after the color development reaction using the complex can be made conspicuous. By making the display portion after the color development reaction conspicuous, the user can accurately and easily grasp the inspection result, and misrecognition by the user can be suppressed.

[0295] The method of introducing the leucorrhea (or leucorrhea components) into the test strip is not particularly limited. For example, it can be introduced by bringing the leucorrhea into local contact with the test strip. In one embodiment, the test strip has a first member that comes into contact with the leucorrhea. In this case, the test strip can be configured such that luteinizing hormone in the leucorrhea moves from the first member through the second member to the display portion of the third member.

[0296] In addition, for a more detailed specific mode of the test strip of Mode 11, reference can be made to other descriptions of the test strip (such as the description of Mode 5 and FIG. 5-1, etc.).

[0297] FIG. 5-4 is a schematic cross-sectional view of an absorbent article according to one mode of the present invention. The test strip has a sample pad, a conjugate pad, and a membrane (including a display portion). When observing the absorbent article from the skin side, the colored area carried on the first skin-side sheet covers the conjugate pad (the second member). In addition, in the mode of the drawing, the pad located on the downstream side of the membrane having the display portion is also covered by the colored area.

[0298] <Mode 12>

[0299] According to the absorbent article according to any one of Modes 9 to 11, wherein,

[0300] The detection is performed by bringing at least a part of the topsheet into direct contact with the vagina.

[0301] According to the invention of Mode 12, since the leucorrhea attached to the vaginal part can be recovered into the absorbent article, even a relatively small amount of leucorrhea can be efficiently detected.

[0302] <Mode 12b>

[0303] In one embodiment of the absorbent article of the present disclosure, the basis weight per unit area of the topsheet is 20 gsm or less.

[0304] According to the invention of this mode, since the basis weight per unit area of the topsheet is small, the leucorrhea, which is a highly viscous liquid substance, can relatively easily pass through the topsheet and contact the test strip. Therefore, even when the discharge amount of leucorrhea is relatively small, for example, the detection can be performed well.

[0305] In addition, according to the invention of this mode, since the basis weight per unit area of the topsheet is relatively small, the visual recognition of the test strip through the topsheet can be ensured.

[0306] In addition, according to the invention of this method, by making the basis weight per unit area of the topsheet relatively small, the topsheet becomes relatively soft. Therefore, the conformability to the wearer's body is improved. Thus, even when leucorrhea adheres to and remains on the wearer's body, the leucorrhea adhering to the body can be transferred to the topsheet due to the wearer's movement or the like. Therefore, even when the discharge amount of leucorrhea is relatively small, it can be brought into contact with the test paper, and thus the detection can be performed well.

[0307] <Mode 12c>

[0308] In one embodiment of the absorbent article of the present disclosure, the thickness of the topsheet is 1 mm or less.

[0309] According to the invention of this method, since the thickness of the topsheet is small, leucorrhea, which is a liquid substance with high viscosity, can relatively easily pass through the topsheet and reach the test paper. Thus, even when the discharge amount of leucorrhea is relatively small, the detection can be performed well.

[0310] In addition, according to the invention of this method, since the thickness of the topsheet is relatively small, the visual recognition of the test paper through the topsheet can be ensured.

[0311] In addition, according to the invention of this method, by making the thickness of the topsheet relatively small, the topsheet becomes relatively soft. Therefore, the conformability to the wearer's body is improved. Thus, even when leucorrhea adheres to and remains on the wearer's body, the leucorrhea adhering to the body can be transferred to the topsheet due to the wearer's movement or the like. Therefore, even for leucorrhea with a relatively small sample amount, the detection can be performed well.

[0312] <Mode 12d>

[0313] In one embodiment of the absorbent article of the present disclosure, the single fiber diameter of the fibers constituting the topsheet is 8.0 dtex or less.

[0314] According to the invention of this method, since the fiber diameter of the topsheet located between the wearer and the test paper is small, the gaps in the topsheet become relatively large. Therefore, leucorrhea, which is a liquid substance with high viscosity, can relatively easily pass through the topsheet and reach the test paper. Thus, even when the discharge amount of leucorrhea is relatively small, the detection can be performed well.

[0315] In addition, according to the invention of this method, by making the fiber diameter of the topsheet relatively small, the topsheet becomes relatively soft. Therefore, the conformability to the wearer's body is improved. Thus, even when leucorrhea adheres to and remains on the wearer's body, the leucorrhea adhering to the body can be transferred to the topsheet due to the wearer's movement or the like. Therefore, even for leucorrhea with a relatively small sample amount, the detection can be performed well.

[0316] The single fiber diameter of the fibers constituting the topsheet is more preferably 5.0 dtex or less, and further preferably 3.0 dtex. If the single fiber diameter of the fibers constituting the topsheet is 3.0 dtex or less, a particularly good skin feel can be obtained.

[0317] <Mode 12e>

[0318] In one embodiment of the absorbent article of the present disclosure,

[0319] The basis weight per unit area of the topsheet described herein is 5 gsm or more,

[0320] The thickness of the topsheet is 0.1 mm or more, and

[0321] The single fiber diameter of the fibers constituting the topsheet is 1.0 dtex or more.

[0322] When the leukorrhea is brought into contact with the test paper through the topsheet, in order to make the leukorrhea with relatively high viscosity contact well with the test paper, it is necessary to improve the permeability of the topsheet.

[0323] In addition, when the leukorrhea is brought into contact with the test paper through the topsheet, it is necessary to ensure the visual recognition of the test paper while ensuring the wearability (touch feeling) of the topsheet.

[0324] Moreover, in order to effectively collect the leukorrhea with a relatively small discharge amount and bring it into contact with the test paper, it is important to ensure the softness of the topsheet so that the leukorrhea attached to the body is transferred to the topsheet (followability) due to the movement of the wearer or the like.

[0325] In contrast, according to the invention of the above-described Mode 12e, an absorbent article can be obtained that satisfies all of these conditions (i.e., "liquid permeability", "visual recognition", "wearability", "followability") that are important for detecting LH well from leukorrhea at a relatively high level.

[0326] <Mode 12f>

[0327] In one embodiment of the absorbent article of the present disclosure,

[0328] The topsheet has an embossed pattern at least partially,

[0329] The width of the test paper is larger than the size and / or interval of each pattern of the embossed pattern.

[0330] When the topsheet is embossed, the fibers constituting the topsheet become thicker due to the embossing, and as a result, the liquid permeability of the leukorrhea and / or the visual recognition through the topsheet decreases at the embossed pattern portion.

[0331] In contrast, in the invention according to Mode 12f, the width of the test strip becomes relatively large, whereby a decrease in permeability and / or visual recognition due to the embossed pattern can be avoided.

[0332] <Mode 12g>

[0333] In one embodiment of the absorbent article of the present disclosure,

[0334] the topsheet partially has an embossed pattern,

[0335] the test strip can come into contact with the leucorrhea through a portion of the topsheet that does not have the embossed pattern.

[0336] In the case of embossing the topsheet, the fibers constituting the topsheet become thicker due to the embossing treatment. As a result, the permeability of the leucorrhea and / or the visual recognition through the topsheet decreases at the embossed pattern portion.

[0337] In contrast, in the invention according to Mode 12g, since the width of the test strip becomes relatively large, a decrease in permeability and / or visual recognition due to the embossed pattern can be avoided.

[0338] <Mode 12h>

[0339] In one embodiment of the absorbent article of the present disclosure,

[0340] the topsheet does not contain TiO 2 .

[0341] According to the invention of this mode, since the visual recognition of the topsheet is further improved, the visual recognition performance of the test strip through the topsheet is further improved.

[0342] <Mode 13>

[0343] According to the absorbent article according to any one of Modes 9 to 12, wherein

[0344] the test strip has a sample pad as a first member that comes into contact with the leucorrhea, and the sample pad is disposed at a position opposite to the wearer's vaginal part during wearing,

[0345] the fiber diameter of the fibers constituting the sample pad is the same as or smaller than the fiber diameter of the fibers constituting the topsheet.

[0346] According to the invention of Mode 13, since solids that cannot be filtered by the topsheet can be filtered by the sample pad, it is easier to detect LH in the leucorrhea.

[0347] <Mode 14>

[0348] The absorbent article according to any one of Aspects 9 to 13, wherein,

[0349] The test strip has a sample pad as a first member that comes into contact with vaginal discharge, and the sample pad is disposed at a position that faces the vaginal part of the wearer during wearing.

[0350] The topsheet and the sample pad are made of a sheet material having fibers.

[0351] The average fiber-to-fiber distance of the topsheet is longer than the average fiber-to-fiber distance of the sample pad.

[0352] According to this aspect, since excrement (especially vaginal discharge) in the topsheet is likely to transfer to the first member (especially the sample pad) with a relatively narrow fiber-to-fiber distance, even a small amount of vaginal discharge can be more easily detected by the test strip.

[0353] <Aspect 15>

[0354] A test strip for an absorbent article, which uses an immunochromatographic method for detecting luteinizing hormone in vaginal discharge, wherein,

[0355] The test strip is configured to infer that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day.

[0356] Similar to the content described above for Aspect 1, according to the test strip of Aspect 15, for example, compared with the case where the LH peak in urine is used as an index, the ovulation day can be grasped from an earlier period. Therefore, the possibility of ensuring a greater chance of natural conception can be increased, and natural conception can be planned in advance. In addition, compared with the conventional method where the ovulation day can be grasped on the ovulation day or the day before, the burden of having to schedule natural conception on the day or the day before or two days before can be reduced, and / or the situation where natural conception cannot be carried out due to inability to plan in advance can be suppressed. As a result, the execution of natural conception can be improved while reducing the mental burden.

[0357] And, since the test strip of Aspect 15 uses an immunochromatographic method for detecting luteinizing hormone in vaginal discharge, compared with the prior art such as using the menstrual cycle as an index, the natural conception period can be grasped with high precision.

[0358] <Aspect 16>

[0359] A test strip for an absorbent article, which uses an immunochromatographic method for detecting luteinizing hormone in vaginal discharge, wherein,

[0360] Luteinizing hormone in the range of 0.05 mIU / mL to 2.5 mIU / mL is detected as positive.

[0361] This test strip that detects luteinizing hormone at a positive level between 0.05 mIU / mL and 2.5 mIU / mL can detect luteinizing hormone in vaginal discharge with relatively high reliability.

[0362] In addition, by using this test strip in an absorbent article, different from the conventional method of detecting luteinizing hormone (LH) in urine, it is possible to predict the ovulation day with relatively high reliability while reducing the burden on the user in terms of not having to consciously collect samples, etc.

[0363] Moreover, by using this test strip in an absorbent article, different from the conventional urine luteinizing hormone (LH) test kit, it is possible to very simply predict the ovulation day. In addition, it also has the effect of causing less psychological resistance.

[0364] Also, in the immunochromatographic method, it sometimes takes a relatively long time (e.g., 10 minutes) for detection. However, by using this test strip in an absorbent article, just by wearing the absorbent article, the detection reaction can be carried out along with the discharge of vaginal discharge, so the prediction of the ovulation day becomes simpler.

[0365] In addition, different from the conventional use of urine, by using this test strip in an absorbent article, it also has the advantage of being able to perform the detection without worrying about getting hands dirty.

[0366] As described above, according to Mode 16, a test strip that can predict the ovulation day more simply than before can be provided.

[0367] In addition, the detailed content of the test strips of Mode 15 and Mode 16 can be referred to the descriptions of the above other modes, especially the descriptions of the absorbent articles of Modes 1 to 14 (especially the descriptions of the test strips).

[0368] The above modes of the present disclosure can be used in combination or alone. For example, at least any one of the above Modes 5b - 5f and at least any one of the above Modes 1 - 16 can be combined.

[0369] <Overview Structure of Absorbent Article>

[0370] The absorbent article 1 of the embodiment will be described with reference to the drawings. The absorbent article can be an absorbent article such as a sanitary pad. In the following embodiments, as an example of the absorbent article, a sanitary pad will be described.

[0371] The absorbent article 1 of FIG. 5-1 may have a longitudinal direction L, a width direction W, and a thickness direction T. The longitudinal direction L is the direction extending from the front side (ventral side) to the back side (dorsal side) of the user or from the back side to the front side of the user. The width direction W is the direction orthogonal to the longitudinal direction L. The thickness direction T is the direction extending from the skin-side of the user to the non-skin-side or from the non-skin-side to the skin-side of the user. Further, the thickness direction T is the direction orthogonal to the longitudinal direction L and the width direction W. The skin-side corresponds to the side facing the user's skin during use. The non-skin-side corresponds to the side opposite to the skin-side during use, i.e., the side facing in the direction opposite to the user's skin.

[0372] As shown in FIG. 5-1, the absorbent article 1 may have a front-side region S1, a back-side region S2, and a central region S3. The front-side region S1 is located at a position anterior to the central region S3, and the back-side region S2 is located at a position posterior to the central region S3. The central region S3 includes the region that abuts against the user's excretory opening (e.g., the vaginal opening). It may be that the anterior region obtained by trisecting the absorbent article 1 in the longitudinal direction L is the front-side region S1, the posterior region is the back-side region S2, and the central region between the front-side region S1 and the back-side region S2 is the central region S3. In the case where the absorbent article 1 has wing parts, the central region S3 may be the region from the front edge of the root of the wing part to the rear edge of the root of the wing part. Additionally, the wing part is the part that is folded back to the non-skin-side of the wearing article when using the absorbent article 1.

[0373] The absorbent article 1 may have an absorbent core (absorbent body) 20, a topsheet 30 (especially a surface sheet 31), a non-skin-side sheet, an adhesive part, and a test paper (inspection member) 60. The absorbent core 20 includes an absorbent material for absorbing liquid. The absorbent material may be constituted by at least one of pulp and superabsorbent polymer, for example.

[0374] The topsheet 30 is disposed at a position closer to the skin-side T1 than the absorbent body 20. The topsheet 30 may be the surface sheet 31 disposed at a position closer to the skin-side than the test paper 60. The surface sheet 31 faces the user's skin. The surface sheet 31 may also be constituted by a plurality of sheets. In an embodiment, the topsheet 30 is constituted by the surface sheet 31. The surface sheet 31 (topsheet 30) may be constituted by, for example, spunlace nonwoven fabric, thermal bonded nonwoven fabric, spunbond nonwoven fabric, SMS nonwoven fabric, etc.

[0375] The visible light transmittance of the surface sheet 31 may be 60% or more. The visible light transmittance of the surface sheet 31 may preferably be 70% or more, and may more preferably be 80% or more. The basis weight of the surface sheet 31 may be 90 gsm or less, may also be 30 gsm or less, and may further be 17 gsm or less. The thickness of the surface sheet 31 may be 5 mm or less.

[0376] The non-skin side sheet 40 is disposed at a position closer to the non-skin surface side than the absorbent core 20. The non-skin side sheet 40 may have a backsheet 41 facing the wearing article. The non-skin side sheet 40 may be formed of, for example, a liquid-impermeable film. In addition, the non-skin side sheet 40 may be a sheet material having liquid impermeability and air permeability, such as a perforated plastic film.

[0377] The adhesive portion is provided on the non-skin surface of the non-skin side sheet 40. The adhesive portion may be provided in a region overlapping the absorbent core 20 in the thickness direction T, or may be provided in a region not overlapping the absorbent core 20 in the thickness direction T. The adhesive portion may be provided on the wing. The absorbent article 1 is fixed to the wearing article by the adhesive portion.

[0378] The structure of the test paper and the like will be described more specifically with reference to FIG. 5-1. The absorbent article 1 in FIG. 5-1 may have an absorbent core 20, a topsheet 30, a backsheet, an adhesive portion, and a test paper (inspection member) 60. The absorbent core 20 contains an absorbent material for absorbing liquid. The absorbent material may be composed of, for example, at least one of pulp and a superabsorbent polymer.

[0379] The test paper (inspection member) 60 in FIG. 5-1 has a display portion (reference numerals 62A and 62B) that can be colored based on excrement (leukorrhea). The test paper 60 has a contact portion (first member, such as a sample pad) 64 for the leukorrhea to contact. The test paper 60 may have a moving portion for the components contained in the leukorrhea (hereinafter, referred to as leukorrhea components) to move. In the moving portion, the leukorrhea components may move according to capillary action. The moving portion may have a display moving portion 66A for the leukorrhea components to move from the contact portion 64 to the display portion (reference numerals 62A and 62B) and a terminal moving portion 66B for the leukorrhea components to move in a direction away from the display portion (reference numerals 62A and 62B). The terminal moving portion is a portion for the leukorrhea components that have passed through the display portion (reference numerals 62A and 62B) to move.

[0380] The contact portion (first member) 64 for contact with vaginal discharge can be constituted by, for example, a pad (which may also be referred to as a sample pad or test sample pad). The components of vaginal discharge in the vaginal discharge that come into contact with the contact portion 64 move, for example, in the pad and are transferred to the second member (for example, the conjugate pad). The conjugate pad contains a labeled antibody that recognizes luteinizing hormone in vaginal discharge. Although not shown in FIG. 5-1, the conjugate pad (second member) can be arranged, for example, to overlap the sample pad (first member) in the thickness direction. The complex formed by the antigen-antibody reaction between the components of vaginal discharge and luteinizing hormone contained in the components of vaginal discharge and the labeled antibody can move in the moving portion 66A according to capillary action. The portion for these substances to move can be constituted by, for example, a membrane. The display portion has a site 62A that contains a capture antibody that captures (binds) the formed complex. This site becomes colored when the complex is captured by the capture antibody. This site 62A of the display portion can be referred to as a test line.

[0381] The display portion can have a site 62B that contains a capture antibody and is different from the site 62A that contains the capture antibody that captures the complex. The capture antibody at the site 62B can capture a complex different from the complex captured at the site 62A, or can capture the labeled antibody. The site 62B becomes colored when capturing the complex or the labeled antibody. The site 62B that captures the labeled antibody can be referred to as a control line. The components of vaginal discharge that have passed through the display portion 62 (that is, the components not captured by the capture antibody) move in the terminal moving portion 66B. The terminal moving portion 66B can be constituted by a membrane. In addition, the terminal moving portion 66B can have an adsorption pad that absorbs the components of vaginal discharge that have passed over the display portion 62. Instead of the adsorption pad, the components of vaginal discharge that have passed over the display portion 62 can be absorbed by the absorption core 20. In the case of using immunochromatography, the display portion 62 and the contact portion 64 are arranged at different positions. Thus, in this case, the display portion 62 and the contact portion 64 are different.

[0382] The test strip (inspection member) 60 only needs to have a member that can hold or contain substances such as a labeled antibody and a capture antibody, and can be constituted by any material such as paper, non-woven fabric, or woven fabric, for example.

[0383] The test strip (inspection member) 60 can be biased to one side in the front-back direction L. As shown in FIG. 5-1, the center CT in the front-back direction L of the inspection member 60 can be located at a position in front of the center CL in the front-back direction L of the absorbent article 1. In addition, the display portions (reference numerals 62A and 62B) can be biased to one side in the front-back direction L. The display portions (reference numerals 62A and 62B) can be located at a position in front of the center CL of the absorbent article 1, and the display portions (reference numerals 62A and 62B) can be located at a position in front of the central region S3. The display portion 62 can be disposed in the front side region S1. Thus, since the display portions (reference numerals 62A and 62B) are disposed at positions away from the excretory opening, it is possible to suppress the color development of the display portions (reference numerals 62A and 62B) from being difficult to visually recognize due to leukorrhea. In particular, in the supine position, leukorrhea is not likely to spread to the front side region S1, so that it is possible to suppress the deterioration of the visual recognition of the color development caused by leukorrhea. In addition, in the inspection member 60 using the immunochromatography method, leukorrhea is not likely to come into direct contact with the display portions (reference numerals 62A and 62B), so that the health state can be displayed with high accuracy.

[0384] In addition, the contact portion 64 can be biased to one side in the front-back direction L. The contact portion 64 can be located at a position in front of the center CL of the absorbent article 1. The contact portion 64 can be disposed in the crotch region (not shown). Since leukorrhea is likely to come into contact with the contact portion 64, the display portion is likely to develop color, and it is easy for the user to confirm the health state. The contact portion 64 can be located at a position on the inner side in the front-back direction L than the display portions (reference numerals 62A and 62B).

[0385] In the test strip 60, regarding the central region located at the center and the two side regions located at both ends when the region of the test strip is equally divided into five in the width direction W, the maximum thickness of the central region can be thicker than the maximum thickness of the side regions, and / or the average thickness of the central region can be thicker than the average thickness of the side regions.

[0386] The test strip (inspection member) is generally configured to have a plurality of members having respective functions such as a moving portion and a display portion. If the respective structural members are offset or rolled up, the inspection accuracy may decrease. When wearing the absorbent article, an external force is applied to the inspection member due to the movement of the wearer or the like, causing deformation, and there may be a displacement and rolling up between the members constituting the inspection member.

[0387] On the other hand, when the maximum thickness and / or the average thickness of the side region is thinner than the maximum thickness and / or the average thickness of the central region, the edge of the inspection member is not likely to be hooked, and sometimes it is possible to suppress the rolling up of the edge of the inspection member and maintain the inspection accuracy.

[0388] In addition, by suppressing the curling and twisting of the edge of the test strip, it is possible to suppress local variations in the thickness and density of each structural member. If the thickness and density vary locally, it may cause the movement of excretory components to stagnate at the varying part or make it difficult to perform a color development reaction. By suppressing local variations in the thickness and density of each structural member, it is sometimes possible to suppress a decrease in inspection accuracy.

[0389] A conceptual diagram of the test strip is shown in FIG. 5-2. For other structures of the test strip, in addition to referring to the above description, reference can also be made to, for example, the description in Patent Document International Application WO2021 / 132724A1.

[0390] FIG. 5-3 is a schematic cross-sectional view of an absorbent article according to one embodiment of the present invention. The test strip (inspection member) is disposed between the topsheet and the absorbent core (absorbent body). In the embodiment shown in the drawing, a second sheet is disposed between the absorbent core and the test strip (inspection member).

[0391]

Examples

[0392] Hereinafter, the present invention will be specifically described with reference to examples. The present invention is not limited by these examples.

[0393] <Reference Example>

[0394] As seen in FIGS. 6-1 to 6-7 and Figure 12 , particularly in FIG. 6-3, according to the test strip of the present invention, since the LH peak in leucorrhea appears at a rate of 86% during the conception window period, it can be known that it can function sufficiently as a biomarker for predicting the ovulation day.

[0395] In particular, FIGS. 6-5 to 6-7 show that the LH peak in leucorrhea can be detected at a period earlier than the LH peak in urine. From this result, it is clear that by using the LH value in leucorrhea as an index, it is possible to grasp the period suitable for natural conception (for example, the period from 5 days before the ovulation day to the ovulation day).

[0396] In addition, the horizontal axis in FIGS. 6-5 to 6-7 represents the number of days when the LH peak value in urine is set to 0 days.

[0397] <Examples>

[0398] As the test strip of the present invention, "Specification 1" and "Specification 2" were produced and their performance was investigated.

[0399] (Standard Solution)

[0400] The LH standard solution uses the casein blocking buffer of LH. Specifically, as the positive test sample solution, "Lumipulse Presto LH LH Calibration Solution (250 mIU)" (Fujirebio Inc.: CODE No. 291573) is used. As the dilution solution, 1% casein, 100 mM borate, pH 8.5 is used, and the positive test sample solution is diluted to an arbitrary concentration with the dilution solution to obtain the standard solution.

[0401] (Sensitivity test)

[0402] Drop the standard solution containing various concentrations of LH onto the sample pad of the test strips of the above Specifications 1 and 2, and confirm the color development of the display part.

[0403] In Figure 1 the results are shown.

[0404] According to the following Figure 1 it can also be known that for Specification 1, when the LH concentration is 0.5 mIU / mL or 1.0 mIU / mL or more, the color development of the display part can be confirmed.

[0405] For Specification 1, at least in the concentration range of 0.5 mIU / mL to 1 mIU / mL, a proportional relationship can be confirmed between the LH concentration and the color development intensity.

[0406] In addition, according to the following Figure 1 it can also be known that for Specification 2, when the LH concentration is 0.05 mIU / mL or 0.1 mIU / mL or more, the color development of the display part can be confirmed.

[0407] For Specification 2, at least in the concentration range of 0.05 mIU / mL to 1.0 mIU / mL, a proportional relationship can be confirmed between the LH concentration and the color development intensity.

[0408] <Comparison>

[0409] Compare the color development intensities of the test strips of Specification 1 (Example 1) and Specification 2 (Example 2).

[0410] In Figure 2 the results are shown. According to Figure 2 it can be known that the test strip of the present invention shows good color development intensity in a wide LH concentration range. The test strip of Example 2 shows better color development intensity than the test strip of Example 1.

[0411] <Leucorrhea test>

[0412] Use the sanitary napkin with the test strips of the above Specifications 1 and 2 to detect the LH in the leucorrhea discharged from the vagina of the wearer.

[0413] The following Figure 3 shows the test results for Specification 1.

[0414] According to Figure 3 it can be seen that when using the test strip of Specification 1, LH can be detected with relatively high precision.

[0415] The following Figure 4 shows the test results for Specification 2.

[0416] According to Figure 4 it can be seen that when using the test strip of Specification 2, LH can also be detected with relatively high precision. In particular, the detection precision of Specification 2 is higher than that of Specification 1.

[0417] <Invention B>

[0418] This disclosure also includes the following invention (“Invention B of the present disclosure” or “Invention B”).

[0419] Invention B relates to an absorbent article.

[0420] <Background Art of Invention B>

[0421] Body fluids such as urine and saliva are used to detect antigens for pregnancy tests, diagnosis of viral infections, diagnosis of bacterial infections, etc.

[0422] For example, in Patent Document (Japanese Patent Laid-Open No. 5-87807), a pregnancy test device is disclosed, which is characterized in that it is composed of a test device main body and a packaging bag for storing the test device main body. The test device main body includes a urine extraction part for contacting and absorbing urine, a reagent part arranged in contact with the urine extraction part, a base material part for allowing the urine extracted by the urine extraction part to move through the reagent part, a determination part for determining whether pregnancy has occurred based on the presence or absence of color development of the urine moving on the base material part, and a fixing member for integrally fixing the urine extraction part, the reagent part, the base material part, and the determination part. The packaging bag includes a component that can be opened in such a way that only the urine extraction part and the determination part of the test device main body are sequentially exposed.

[0423] <Problems to be Solved by Invention B>

[0424] Including the pregnancy test device disclosed in Patent Document (Japanese Patent Laid-Open No. 5-87807), in a usual pregnancy test drug, in order to measure whether pregnancy has occurred, human chorionic gonadotropin (hCG), which is an antigen contained in urine, is measured. By using urine, the amount of the antigen can be measured simply.

[0425] However, generally speaking, it is known that the higher the amount of water obtained, the lower the concentration of the components in urine. The concentration of the components in urine decreases due to a decrease in the amount of water obtained or an increase in sweating, and the concentration of the antigen in urine also tends to change. Therefore, in the case of using a pregnancy test drug for urine, it is recommended to measure in the morning when the concentration of hCG in urine is high.

[0426] In vaginal discharge, it is generally considered that the change in the amount of antigen caused by factors such as the amount of water obtained is less compared to urine. Therefore, if the antigen in vaginal discharge can be simply detected, it is considered that the detection accuracy of the antigen will be improved. In addition, if the antigen in vaginal discharge can be simply detected, the options for detecting the antigen are expanded, so it is considered meaningful. And when the antigen contained in vaginal discharge is also contained in urine, it is expected to improve the detection accuracy of the antigen by detecting both the antigen in vaginal discharge and the antigen in urine.

[0427] On the other hand, since vaginal discharge usually cannot be controlled by the will of the excretor, there is a tendency that it takes time to detect the antigen contained in vaginal discharge.

[0428] In addition, since the vaginal orifice and the urinary orifice are located in close proximity, the detection of the antigen contained in vaginal discharge tends to be easily affected by urine.

[0429] Therefore, an object of the present disclosure is to provide an absorbent article that can detect the antigen contained in vaginal discharge in a state not easily affected by urine.

[0430] <Solution for Solving the Problems of Invention B>

[0431] The present inventors have found the following Invention B (Modes B1 to B14):

[0432] <Mode B1>

[0433] An absorbent article, which has a test strip for detecting the antigen contained in vaginal discharge and has a thickness direction, and is characterized in that

[0434] the absorbent article sequentially includes a liquid-permeable topsheet, the test strip, an absorbent body, and a liquid-impermeable backsheet in the thickness direction,

[0435] the test strip sequentially includes a sample pad that inhibits the antigen-antibody reaction by hindering the mucin contained in the vaginal discharge, a conjugate pad having a labeled antibody, and a developing membrane having an immobilized antibody in the thickness direction,

[0436] the sample pad or the conjugate pad is in direct contact with the absorbent body or is indirectly in contact with the absorbent body via a liquid-permeable sheet.

[0437] <Mode B2>

[0438] The absorbent article according to Mode B1, wherein,

[0439] The antigen contained in the vaginal excrement is also contained in urine.

[0440] <Mode B3>

[0441] The absorbent article according to Mode B1 or B2, wherein,

[0442] The test strip further has a transfer inhibition lower layer between the development layer and the absorbent body, and the transfer inhibition lower layer inhibits the transfer of the excrement of the wearer absorbed by the absorbent body to the development layer.

[0443] <Mode B4>

[0444] The absorbent article according to any one of Modes B1 to B3, wherein,

[0445] The test strip further has a transfer inhibition upper layer between the development layer and the topsheet to inhibit the transfer of the excrement of the wearer to the development layer.

[0446] <Mode B5>

[0447] The absorbent article according to any one of Modes B1 to B4, wherein,

[0448] The test strip further has a transfer inhibition upper layer between the development layer and the topsheet to inhibit the transfer of the excrement of the wearer to the development layer, and the test strip further has a transfer inhibition lower layer between the development layer and the absorbent body to inhibit the transfer of the excrement absorbed by the absorbent body to the development layer,

[0449] The test strip has a sealing portion for sealing the outer edge of the transfer inhibition upper layer and the outer edge of the transfer inhibition lower layer.

[0450] <Mode B6>

[0451] The absorbent article according to any one of Modes B1 to B5, wherein,

[0452] The fiber density of the sample pad is higher than that of the topsheet.

[0453] <Mode B7>

[0454] The absorbent article according to any one of Modes B1 to B6, wherein,

[0455] The hydrophilicity of the sample pad is higher than that of the topsheet.

[0456] <Mode B8>

[0457] The absorbent article according to any one of modes B1 to B7, wherein,

[0458] The sample pad is in contact with the absorbent body, and the fiber density of the absorbent body is higher than that of the sample pad.

[0459] <Mode B9>

[0460] The absorbent article according to any one of modes B1 to B8, wherein,

[0461] The sample pad is in contact with the absorbent body, and the hydrophilicity of the absorbent body is higher than that of the sample pad.

[0462] <Mode B10>

[0463] The absorbent article according to any one of modes B1 to B9, wherein,

[0464] The fiber density of the conjugate pad is higher than that of the sample pad.

[0465] <Mode B11>

[0466] The absorbent article according to any one of modes B1 to B10, wherein,

[0467] The hydrophilicity of the conjugate pad is higher than that of the sample pad.

[0468] <Mode B12>

[0469] The absorbent article according to any one of modes B1 to B11, wherein,

[0470] The spreading layer is not in direct contact with the absorbent body.

[0471] <Mode B13>

[0472] An absorbent article that includes a test strip for detecting an antigen contained in vaginal excrement and has a thickness direction, characterized in that,

[0473] The absorbent article sequentially includes a liquid-permeable topsheet, the test strip, an absorbent body, and a liquid-impermeable backsheet in the thickness direction,

[0474] The test strip further includes a transfer inhibition lower layer between the test strip and the absorbent body that inhibits the transfer of excrement from the wearer absorbed by the absorbent body to the test strip.

[0475] <Mode B14>

[0476] The absorbent article according to mode B13, wherein,

[0477] The test strip further has a transfer-inhibiting upper layer between the test strip and the top sheet that inhibits the transfer of excreta other than the vaginal excreta of the wearer to the test strip.

[0478] <Effect of Invention B>

[0479] The absorbent article of Invention B can detect an antigen contained in vaginal excreta in a state not easily affected by urine.

[0480] <Mode for Carrying Out Invention B>

[0481] Specifically, the Invention B of the present disclosure relates to the following mode.

[0482] [Mode B1]

[0483] An absorbent article having a test strip for detecting an antigen contained in vaginal excreta and having a thickness direction, characterized in that

[0484] the absorbent article sequentially includes a liquid-permeable top sheet, the test strip, an absorbent body, and a liquid-impermeable bottom sheet in the thickness direction,

[0485] the test strip sequentially includes a sample pad that inhibits an antigen-antibody reaction by mucin contained in the vaginal excreta, a conjugate pad having a labeled antibody, and a developing membrane having an immobilized antibody in the thickness direction,

[0486] the sample pad or the conjugate pad is in direct contact with the absorbent body or is in indirect contact with the absorbent body via a liquid-permeable sheet.

[0487] In the absorbent article, vaginal excreta (such as leucorrhea or menstrual blood) reaches the sample pad of the test strip after passing through the liquid-permeable sheet after reaching the liquid-permeable sheet. In the sample pad, the vaginal excreta is treated to inhibit the antigen-antibody reaction by mucin contained in the vaginal excreta, and the vaginal excreta is transferred to the conjugate pad. In the conjugate pad, an antigen contained in the vaginal excreta is bound to the labeled antibody in the conjugate pad to form an immune complex, and the immune complex is transferred to the developing membrane. In the developing membrane, the antigen is detected by binding the immune complex to the immobilized antibody and developing color.

[0488] On the other hand, since the vaginal orifice and the urinary orifice are in close positions, the absorbent article sometimes absorbs the urine of the wearer, and sometimes the urine absorbed by the absorbent article reaches the test strip and has an adverse effect on the detection of the antigen.

[0489] In the above absorbent article, since the sample pad or conjugate pad is in direct contact with the absorbent body or is in indirect contact with the absorbent body through a liquid-permeable sheet, urine reaching the sample pad of the test strip can be transferred to the absorbent body. Thus, the above absorbent article can detect the antigen contained in vaginal excretions in a state not easily affected by urine.

[0490] [Mode B2]

[0491] The absorbent article according to Mode B1, wherein,

[0492] The above antigen contained in the above vaginal excretions is also contained in urine.

[0493] In the above absorbent article, since the antigen contained in the vaginal excretions as the detection object is also contained in urine, urine tends to affect the detection of the antigen contained in the vaginal excretions.

[0494] In the above absorbent article, since the sample pad or conjugate pad is in direct contact with the absorbent body or is in indirect contact with the absorbent body through a liquid-permeable sheet, urine reaching the sample pad of the test strip can be transferred to the absorbent body. Thus, the above absorbent article can detect the antigen contained in vaginal excretions in a state not easily affected by urine.

[0495] [Mode B3]

[0496] The absorbent article according to Mode B1 or B2, wherein,

[0497] The above test strip further has a transfer inhibition lower layer between the above development layer and the above absorbent body, and the transfer inhibition lower layer inhibits the transfer of the wearer's excretions absorbed by the above absorbent body to the above development layer.

[0498] Since the above absorbent article has a predetermined transfer inhibition lower layer, it can inhibit the transfer of the wearer's excretions absorbed by the absorbent body, such as vaginal excretions, urine, feces, etc., to the development layer. As a result, the above absorbent article can detect the antigen contained in vaginal excretions in a state not easily affected by urine.

[0499] [Mode B4]

[0500] The absorbent article according to any one of Modes B1 to B3, wherein,

[0501] The above test strip further has a transfer inhibition upper layer between the above development layer and the above topsheet to inhibit the transfer of the wearer's excretions to the above development layer.

[0502] Since the above absorbent article has a predetermined transfer-inhibiting upper layer, it can inhibit the transfer of the wearer's excreta, such as vaginal excreta, urine, feces, etc., directly to the development layer without passing through the sample pad and the conjugate pad. As a result, the above absorbent article can detect the antigen contained in the vaginal excreta in a state not easily affected by the excreta.

[0503] [Mode B5]

[0504] The absorbent article according to any one of Modes B1 to B4, wherein

[0505] The test strip further has a transfer-inhibiting upper layer that inhibits the transfer of the wearer's excreta to the development layer between the development layer and the topsheet, and the test strip further has a transfer-inhibiting lower layer that inhibits the transfer of the excreta absorbed by the absorbent body to the development layer between the development layer and the absorbent body.

[0506] The test strip has a sealing portion that seals the outer edge of the transfer-inhibiting upper layer and the outer edge of the transfer-inhibiting lower layer.

[0507] In the above absorbent article, since the test strip has a transfer-inhibiting upper layer, a transfer-inhibiting lower layer, and a sealing portion that seals their outer edges, it can inhibit the transfer of the wearer's excreta, such as vaginal excreta, urine, feces, etc., directly to the development layer without passing through the sample pad and the conjugate pad. As a result, the above absorbent article can detect the antigen contained in the vaginal excreta in a state not easily affected by the excreta.

[0508] [Mode B6]

[0509] The absorbent article according to any one of Modes B1 to B5, wherein

[0510] The fiber density of the above sample pad is higher than the fiber density of the above topsheet.

[0511] The above absorbent article facilitates the transfer of vaginal excreta from the topsheet to the sample pad.

[0512] [Mode B7]

[0513] The absorbent article according to any one of Modes B1 to B6, wherein

[0514] The hydrophilicity of the above sample pad is higher than the hydrophilicity of the above topsheet.

[0515] The above absorbent article facilitates the transfer of vaginal excreta from the topsheet to the sample pad.

[0516] [Mode B8]

[0517] The absorbent article according to any one of Modes B1 to B7, wherein

[0518] The above sample pad is in contact with the above absorber, and the fiber density of the above absorber is higher than that of the above sample pad.

[0519] The above absorbent article facilitates the escape of urine from the sample pad to the absorber.

[0520] [Mode B9]

[0521] The absorbent article according to any one of Modes B1 to B8, wherein

[0522] The above sample pad is in contact with the above absorber, and the hydrophilicity of the above absorber is higher than that of the above sample pad.

[0523] The above absorbent article facilitates the escape of urine from the sample pad to the absorber.

[0524] [Mode B10]

[0525] The absorbent article according to any one of Modes B1 to B9, wherein

[0526] The fiber density of the above conjugate pad is higher than that of the above sample pad.

[0527] The above absorbent article facilitates the escape of urine from the conjugate pad to the absorber.

[0528] [Mode B11]

[0529] The absorbent article according to any one of Modes B1 to B10, wherein

[0530] The hydrophilicity of the above conjugate pad is higher than that of the above sample pad.

[0531] The above absorbent article facilitates the escape of urine from the conjugate pad to the absorber.

[0532] [Mode B12]

[0533] The absorbent article according to any one of Modes B1 to B11, wherein

[0534] The above expansion layer is not in direct contact with the above absorber.

[0535] The test paper of the above absorbent article is not easily affected by excrement.

[0536] [Mode B13]

[0537] An absorbent article that includes a test paper for detecting an antigen contained in vaginal excrement and has a thickness direction, characterized in that

[0538] The above absorbent article sequentially includes a liquid-permeable topsheet, the above test paper, an absorber, and a liquid-impermeable backsheet in the above thickness direction.

[0539] The above-mentioned test strip further has a transfer-inhibition lower layer between the above-mentioned test strip and the above-mentioned absorber, which inhibits the transfer of the excrement of the wearer absorbed by the above-mentioned absorber to the above-mentioned test strip.

[0540] Since the above-mentioned absorbent article has a predetermined transfer-inhibition lower layer, it can inhibit the transfer of the excrement of the wearer absorbed by the absorber, such as vaginal excrement, urine, feces, etc., to the test strip. As a result, the above-mentioned absorbent article can detect the antigen contained in the vaginal excrement in a state not easily affected by urine.

[0541] [Mode B14]

[0542] The absorbent article according to Mode B13, wherein

[0543] The above-mentioned test strip further has a transfer-inhibition upper layer between the above-mentioned test strip and the above-mentioned topsheet, which inhibits the transfer of the excrement of the wearer other than the above-mentioned vaginal excrement to the above-mentioned test strip.

[0544] Since the above-mentioned absorbent article has a predetermined transfer-inhibition upper layer, it can inhibit the transfer of the excrement of the wearer other than the vaginal excrement to the test strip. As a result, the above-mentioned absorbent article can detect the antigen contained in the vaginal excrement in a state not easily affected by the excrement.

[0545] Description of reference numerals

[0546] 1. Absorbent article (sanitary napkin); 3, 20. Topsheet; 5. Backsheet; 7, 20. Absorber; 9. Second sheet; 21, 60. Test strip; 23, 64. Sample pad (first member); 25. Conjugate pad; 66A. Moving part (display moving part); 66B. Moving part (terminal moving part); 27. Unfolding film; 31. Transfer-inhibition upper layer; 33. Transfer-inhibition lower layer; 35. Covering tape; 101. Fixing part; L. Front-back direction; W. Width direction; CL. Center CT in the front-back direction L of the absorbent article; CT. Center CT in the front-back direction L of the test strip; SR; S1. Front side area of the absorbent article; S2. Rear side area of the absorbent article; S3. Central area of the absorbent article.

Claims

1. An absorbent article having a test strip that uses an immunochromatographic method for detecting luteinizing hormone (LH) from vaginal discharge, wherein, the test strip is configured to infer that the wearer of the absorbent article is in the period from 5 days before the ovulation day to the ovulation day.

2. An absorbent article having a test strip that uses an immunochromatographic method for detecting luteinizing hormone from vaginal discharge ， wherein, for the absorbent article according to claim 1, the test strip detects luteinizing hormone at 0.05 mIU / mL to 10 mIU / mL as positive.

3. An absorbent article having a test strip that uses an immunochromatographic method for detecting luteinizing hormone from vaginal discharge, wherein, the test strip detects luteinizing hormone at 0.05 mIU / mL to 2.5 mIU / mL as positive.

4. The absorbent article according to any one of claims 1 to 3, wherein, the test strip has a width of 10 mm or less.

5. The absorbent article according to any one of claims 1 to 4, wherein, the test strip has: a second member that contains a labeled antibody that recognizes luteinizing hormone in vaginal discharge; and a third member that has a display portion containing a capture antibody, the capture antibody being capable of capturing a complex formed by the binding of the labeled antibody and luteinizing hormone, the test strip being configured such that luteinizing hormone in the vaginal discharge moves from the second member to the display portion of the third member, and being configured such that the capture antibody captures the complex, whereby the display portion of the third member develops color.

6. The absorbent article according to claim 5, wherein, the labeled antibody has a coloring agent with a particle size of 250 nm to 500 nm.

7. The absorbent article according to claim 5 or 6, wherein, the test strip has a moving portion that connects the second member and the display portion, and has a first direction that is the moving direction of vaginal discharge components from the moving portion to the display portion, a second direction that is orthogonal to the first direction, and a thickness direction that is orthogonal to the first direction and the second direction, the test strip has a central region that is located at the center in the second direction and side regions that are located at both ends in the second direction in a region obtained by dividing the test strip into five equal parts in the second direction, the moving portion and the display portion are disposed at least in the central region and the side regions, the maximum thickness of the central region is thicker than the maximum thickness of the side regions, and / or the average thickness of the central region is thicker than the average thickness of the side regions.

8. The absorbent article according to any one of claims 5 to 7, wherein, the display portion of the test strip is visually recognizable from the skin side of the absorbent article, the test strip includes: a transfer-inhibiting upper layer that inhibits the transfer of the wearer's excreta to the display portion of the test strip; and a transfer-inhibiting lower layer that inhibits the transfer of the wearer's excreta to the display portion, the transfer-inhibiting upper layer and the transfer-inhibiting lower layer abut against each other on the outside of the test strip in the width direction of the test strip.

9. The absorbent article according to any one of claims 1 to 8, wherein, The absorbent article has a topsheet, When using the absorbent article, leukorrhea reaches the test strip via the topsheet.

10. The absorbent article according to claim 9, wherein, The absorbent article has a front-back direction, a width direction orthogonal to the front-back direction, and a thickness direction orthogonal to the front-back direction and the width direction, In the thickness direction, from the skin side of the wearer during use, there are further provided the topsheet and an absorbent body containing an absorbent material in sequence, The test strip is disposed between the topsheet and the absorbent body.

11. The absorbent article according to claim 9 or 10, wherein, The test strip has: a second member containing a labeled antibody that recognizes luteinizing hormone in leukorrhea; and a third member having a display portion containing a capture antibody, The capture antibody can capture the complex formed by the binding of the labeled antibody and luteinizing hormone, The test strip is configured such that luteinizing hormone in the leukorrhea moves from the second member to the display portion of the third member, and is configured such that by capturing the complex with the capture antibody, the display portion of the third member develops color, A skin-side sheet having a colored area is disposed at a position closer to the skin side than the test strip, The labeled antibody in the second member of the test strip has a coloring agent, and When viewed from the skin side, the labeled antibody in the second member is covered by the colored area of the skin-side sheet.

12. The absorbent article according to any one of claims 9 to 11, wherein, The detection is performed by bringing at least a part of the topsheet into direct contact with the vagina.

13. The absorbent article according to any one of claims 9 to 12, wherein, The test strip has a sample pad as a first member that comes into contact with leukorrhea, and the sample pad is disposed at a position opposite to the vaginal part of the wearer during wearing, The fiber diameter of the fibers constituting the sample pad is the same as or smaller than the fiber diameter of the fibers constituting the topsheet.

14. The absorbent article according to any one of claims 9 to 13, wherein, The test strip has a sample pad as a first member that comes into contact with leukorrhea, and the sample pad is disposed at a position opposite to the vaginal part of the wearer during wearing, The topsheet and the sample pad are made of a sheet material having fibers, The average fiber-to-fiber distance of the topsheet is longer than the average fiber-to-fiber distance of the sample pad.

15. A test strip for an absorbent article, which uses an immunochromatographic method for detecting luteinizing hormone in leukorrhea, wherein, The test strip is configured to infer that the wearer of the absorbent article is in the period from 5 days before ovulation day to ovulation day.

16. A test strip for an absorbent article, which uses an immunochromatographic method for detecting luteinizing hormone in leukorrhea, wherein, Luteinizing hormone of 0.05 mIU / mL to 2.5 mIU / mL is detected as positive.

Images